WO2026099754 - METHOD FOR REDUCING VIRUS SHEDDING, TISSUE COLONIZATION, AND LYMPHOID DEPLETION CAUSED BY OR ASSOCIATED WITH PCV2 INFECTION
National phase entry is expected:
Publication Number
WO/2026/099754
Publication Date
15.05.2026
International Application No.
PCT/IB2025/061297
International Filing Date
05.11.2025
Title **
[English]
METHOD FOR REDUCING VIRUS SHEDDING, TISSUE COLONIZATION, AND LYMPHOID DEPLETION CAUSED BY OR ASSOCIATED WITH PCV2 INFECTION
[French]
MÉTHODE DE RÉDUCTION DE L'EXCRÉTION VIRALE, DE COLONISATION DE TISSU ET DE DÉPLÉTION LYMPHOÏDE PROVOQUÉES PAR OU ASSOCIÉES À UNE INFECTION PAR PCV2
Applicants **
BOEHRINGER INGELHEIM VETMEDICA GMBH
Inventors
PATTERSON, Abby, Rae
LEITE, Fernando, Lopes Leivas
CUTLER, Timothy, Dean
EICHMEYER, Marc, Allan
KENT, Kevin, Patrick
Priority Data
63/716,995
06.11.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2606 | |
| EPO | Filing, Examination, Granting | 13682 | |
| Japan | Filing, Examination, Granting | 2401 | |
| South Korea | Filing, Examination, Granting | 2575 | |
| USA | Filing, Examination, Granting | 6540 |
Total:
27,804
Contact Us
Abstract[English]
The present invention in particular relates to a method for reducing virus shedding, colonization of lymphoid tissue, and/or lymphoid depletion caused by or associated with a porcine circovirus type 2 (PCV2) infection in a pig, the method comprising administering orally to the pig an immunogenic composition comprising non-replicating PCV2 antigen. In one example, an immunogenic composition is administered via the oral route to a pig, wherein the immunogenic composition comprises a recombinantly produced and purified PCV2 ORF2 protein. This allows to simply reduce virus shedding, colonization of lymphoid tissue, and/or lymphoid depletion caused by associated with a PCV2 infection in the pigs, while simultaneously reducing the propensity for adverse reactions, eliminating the risk of injection site reactions, avoiding pain, and putting less stress on the animals.[French]
La présente invention concerne en particulier une méthode de réduction de l'excrétion virale, de colonisation du tissu lymphoïde et/ou de déplétion lymphoïde provoquées par ou associées à une infection par le circovirus porcin type 2 (PCV2) chez un porc, la méthode consistant à administrer par voie orale au porc une composition immunogène comprenant un antigène PCV2 non réplicatif. Dans un exemple, une composition immunogène est administrée par voie orale à un porc, la composition immunogène comprenant une protéine ORF2 PCV2 produite et purifiée de manière recombinée. Ceci permet de réduire simplement l'excrétion virale, la colonisation du tissu lymphoïde et/ou la déplétion lymphoïde provoquées par une infection par PCV2 chez les porcs, tout en réduisant simultanément la propension à des réactions indésirables, en éliminant le risque de réactions du site d'injection, en évitant la douleur, et en induisant moins de stress chez les animaux.